New RSV vaccines for older adults can result in individual and societal cost savings, benefits
New research from David Hutton
Vaccination against respiratory syncytial virus for adults over 60 is likely cost-effective by preventing illness, hospitalizations, lost quality of life and deaths, according to new research.